ArticleEuropean radiology2026
Performance of a screening-trained DL model for pulmonary nodule malignancy estimation of incidental clinical nodules.
Article in European radiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Deep learning-based differentiation of non-tuberculous mycobacterial lung disease and pulmonary tuberculosis using chest CT.Frontiers in medicine · 2026Article
Corrections and comments
- Commented on by
Authors and funding
8 authors.
Funding
Abstract
objectiveTo test the performance of a DL model developed and validated for screen-detected pulmonary nodules on incidental nodules detected in a clinical setting. MATERIALS AND
methodsA retrospective dataset of incidental pulmonary nodules sized 5-15 mm was collected, and a subset of size-matched solid nodules was selected. The performance of the DL model was compared to the Brock model. AUCs with 95% CIs were compared using the DeLong method. Sensitivity and specificity were determined at various thresholds, using a 10% threshold for the Brock model as reference. The model's calibration was visually assessed.
resultsThe dataset included 49 malignant and 359 benign solid or part-solid nodules, and the size-matched dataset included 47 malignant and 47 benign solid nodules. In the complete dataset, AUCs [95% CI] were 0.89 [0.85, 0.93] for the DL model and 0.86 [0.81, 0.92] for the Brock model (p = 0.27). In the size-matched subset, AUCs of the DL and Brock models were 0.78 [0.69, 0.88] and 0.58 [0.46, 0.69] (p < 0.01), respectively. At a 10% threshold, the Brock model had a sensitivity of 0.49 [0.35, 0.63] and a specificity of 0.92 [0.89, 0.94]. At a threshold of 17%, the DL model matched the specificity of the Brock model at the 10% threshold, but had a higher sensitivity (0.57 [0.43, 0.71]). Calibration analysis revealed that the DL model overestimated the malignancy probability.
conclusionThe DL model demonstrated good discriminatory performance in a dataset of incidental nodules and outperformed the Brock model, but may need recalibration for clinical practice. KEY POINTS: Question What is the performance of a DL model for pulmonary nodule malignancy risk estimation developed on screening data in a dataset of incidentally detected nodules? Findings The DL model performed well on a dataset of nodules from clinical routine care and outperformed the Brock model in a size-matched subset. Clinical relevance This study provides further evidence about the potential of DL models for risk stratification of incidental nodules, which may improve nodule management in routine clinical practice.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.